Biogen Gives Sage Therapeutics $1.5 Billion In Deal To Develop Depression And Tremor Treatments | The Healthcare Technology Report.
FDA approval for zuranolone offers hope in postpartum depression
Sage rethinks SAGE-217 program after phase 3 failure | Fierce Biotech
Sage Stock: FDA Documents Suggest Its Battle In Depression Will Be Trickier Than Expected | Investor's Business Daily
Biotech layoffs 2023: Sage Therapeutics cuts nearly half its staff in wake of partial FDA rejection - Boston Business Journal
Sage Therapeutics plunges after FDA decision on depression drug
Layoffs as Sage Therapeutics reshuffles CNS pipeline
Sage Therapeutics CEO: Mental health is integral to returning to work
Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected
Sage Therapeutics wins priority review for intravenous postpartum depression drug - MassDevice
Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected
Sage Therapeutics - Timberline Construction
Sage Therapeutics (@SageBiotech) / X
Biogen-Sage Therapeutics postpartum depression pill priced at $15,900 | Reuters
Sage Therapeutics CEO on drugs in development, addressing mental health
Why Is Sage Therapeutics (SAGE) Stock Down 48% Today? | InvestorPlace
Sage Therapeutics and Biogen pursue FDA approval for zuranolone
/cloudfront-us-east-1.images.arcpublishing.com/bostonglobe/5L4UQNLAORLRMH6HCPVSUTPQUE.JPEG "Sage Therapeutics to lay off about 40 percent of its workforce - The Boston Globe")
Sage Therapeutics to lay off about 40 percent of its workforce - The Boston Globe
Sage Therapeutics fires 40% of staff after FDA rejected MDD bid - Pharmaceutical Technology
/cloudfront-us-east-2.images.arcpublishing.com/reuters/IXYUV47KYRP5DGR3BXFFW4NLJE.jpg "Sage Therapeutics to cut about 188 jobs after depression drug setback | Reuters")
Sage Therapeutics to cut about 188 jobs after depression drug setback | Reuters
Sage Therapeutics
Sage Therapeutics (@SageBiotech) / X
Sage Therapeutics Restructures To Support ZURZUVAE Launch | Contract Pharma
